際際滷

際際滷Share a Scribd company logo

2010 One Page Ad

Osie Gaines, III
Osie Gaines, III

The protocol-specific eClinical solution used to train investigators, initiate sites, and maintain study compliance. The demonstration is energetic, interactive, and brief. Please, contact me at osie.gaines@firecrestclinical.com to schedule a presentation for you and your Clinical Team!

1 of 1
The eClinical Solution Created by Investigators for Investigators The Firecrest solution has been utilized in over 160 studies in 68 countries. We offer: Fast deployment of an easy-to-use one-stop- shop for clinical trial information Effective, virtual site training to improve protocol compliance and trial results Suite of tools for end users: interactive decision trees, lab manuals, and calculators Robust reporting for the Sponsor team Expertise in many therapeutic areas Global impact-localization into 10 languages Security in a 21 CFR Part 11 compliant system 24/7 support via a flexible web-based portal Our satisfied customers include 8 of the 10 Largest Pharmaceutical orgs. They experience: Fewer Study Start-Up delays A reduction in protocol deviations and site queries to Monitors (CRAs) Increased impact from investigator meetings, while reducing costs Reduced trial costs by 10-25%* *Based on 2-year, Phase III Oncology study Let our team impact your upcoming trials!

More Related Content

2010 One Page Ad

  • 1. The eClinical Solution Created by Investigators for Investigators The Firecrest solution has been utilized in over 160 studies in 68 countries. We offer: Fast deployment of an easy-to-use one-stop- shop for clinical trial information Effective, virtual site training to improve protocol compliance and trial results Suite of tools for end users: interactive decision trees, lab manuals, and calculators Robust reporting for the Sponsor team Expertise in many therapeutic areas Global impact-localization into 10 languages Security in a 21 CFR Part 11 compliant system 24/7 support via a flexible web-based portal Our satisfied customers include 8 of the 10 Largest Pharmaceutical orgs. They experience: Fewer Study Start-Up delays A reduction in protocol deviations and site queries to Monitors (CRAs) Increased impact from investigator meetings, while reducing costs Reduced trial costs by 10-25%* *Based on 2-year, Phase III Oncology study Let our team impact your upcoming trials!